Biotech Company Auxilium Explodes After Takeover Offer

Shares of specialty biopharmaceutical company Auxilium were up more than 42% in after the company received a takeover bid from Irish drug company Endo Pharmaceuticals worth $US2.2 billion.

The offer values Auxilium at $US28.10 per share and is comprised of an equal mix of cash and Endo stock.

Endo’s offer represents a 31% premium to Auxilium’s closing price on Tuesday, and a 40% premium to the closing price of Auxilium over the last 30 days. In after hours trade on Tuesday Auxilium shares were trading as high as $US30.70.

Following the announcement, Endo shares were also higher, up more than 4%.

The offer also follows an announcement from Auxilium last week that the company would cut 30% of its staff as part of cost-saving measures aimed as saving $US75 million per year.

Auxilium’s portfolio of drugs includes: edex®, an injectable treatment for erectile dysfunction, Osbon® ErecAid®, a device for aiding erectile dysfunction, STENDRA®, an oral erectile dysfunction therapy, TESTOPEL®, a long-acting implantable testosterone replacement therapy, XIAFLEX®, for the treatment of Peyronie’s disease and XIAFLEX for the treatment of Dupuytren’s contracture, among other drugs.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.